Front. Immunol., 11 February 2014 | doi: 10.3389/fimmu.2014.00046
Benjamin D. Singer- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA
Regulatory T cells (Tregs) suppress exuberant immune system activation and promote immunologic tolerance. Because Tregs modulate both innate and adaptive immunity, the biomedical community has developed an intense interest in using Tregs for immunotherapy. Conditions that require clinical tolerance to improve outcomes – autoimmune disease, solid organ transplantation, and hematopoietic stem cell transplantation – may benefit from Treg immunotherapy. Investigators have designed ex vivo strategies to isolate, preserve, expand, and infuse Tregs. Protocols to manipulate Treg populations in vivo have also been considered. Barriers to clinically feasible Treg immunotherapy include Treg stability, off-cell effects, and demonstration of cell preparation purity and potency. Clinical trials involving Treg adoptive transfer to treat graft versus host disease preliminarily demonstrated the safety and efficacy of Treg immunotherapy in humans. Future work will need to confirm the safety of Treg immunotherapy and establish the efficacy of specific Treg subsets for the treatment of immune-mediated disease.
Keywords: regulatory T cells, immunotherapeutics, inflammation, tolerance, adoptive transfer, expansion
Citation: Singer BD, King LS and D’Alessio FR (2014) Regulatory T cells as immunotherapy.Front. Immunol. 5:46. doi: 10.3389/fimmu.2014.00046
Received: 16 December 2013; Paper pending published: 13 January 2014;
Accepted: 27 January 2014; Published online: 11 February 2014.
Accepted: 27 January 2014; Published online: 11 February 2014.
Edited by:
Nurit Hollander, Tel Aviv University, Israel
Reviewed by:
Luuk Hilbrands, Radboud University Nijmegen Medical Centre, NetherlandsShimon Slavin, International Center for Cell Therapy & Cancer Immunotherapy, Israel
Copyright: © 2014 Singer, King and D’Alessio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Benjamin D. Singer, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, 5501 Hopkins Bayview Circle, Fourth Floor, Baltimore, MD 21224, USA e-mail: bsinger9@jhmi.edu
No comments:
Post a Comment